Biotech Breakthroughs, Big Buyouts, Immunotherapy Momentum, and a Media Megamerger
Rhea-AI Summary
Kraig Biocraft Laboratories (OTCQB:KBLB) gained national visibility after its recombinant spider silk platform was featured on National Geographic’s March 2026 cover. Kraig plans to deploy ~1 million proprietary silkworm eggs across three Vietnam facilities targeting up to 10 metric tons of cocoons per month from March.
Other market moves include Gilead’s definitive acquisition offer for Arcellx and ImmunityBio reporting strong ANKTIVA revenue growth.
Positive
- Kraig targeting 10 metric tons of cocoons per month starting March
- ImmunityBio ANKTIVA revenue ~$113M in 2025 (+700% YoY)
- Gilead agreed to acquire Arcellx for ~$7.8B implied equity value
- DOJ granted unconditional antitrust clearance for Getty–Shutterstock merger
Negative
- U.K. Competition and Markets Authority decision on Getty–Shutterstock pending by April 19, 2026
- Arcellx anito-cel FDA PDUFA action date set for Dec 23, 2026, creating timing uncertainty
DENVER, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Wall Street opens to a convergence of science, scale, and strategic consolidation. From spider silk making mainstream headlines to multibillion-dollar oncology deals and accelerating immunotherapy revenues, today’s tape reflects capital flowing toward platforms with validation.
Kraig Biocraft Laboratories Featured on National Geographic Cover
Shares of Kraig Biocraft Laboratories (OTCQB:KBLB) could see elevated interest after the company’s recombinant spider silk technology landed on the cover of the March 2026 issue of National Geographic.
The feature, The Quest for Spider Silk, spotlighted Kraig’s genetically enhanced silkworm platform, engineered to spin recombinant spider silk as part of the animal’s natural biological process. The coverage included facility tours and demonstrations such as towing a car and suspending a person using a lightweight loop of spider silk thread.
The visibility comes at a pivotal moment. Kraig is preparing to deploy approximately one million proprietary silkworm eggs across three facilities in Vietnam, targeting up to 10 metric tons of cocoons per month beginning in March.
Scientific validation for the platform was previously published in the Proceedings of the National Academy of Sciences, confirming fibers tougher than conventional silk and comparable to native spider dragline silk.
If commercial output scales as projected, KBLB could become only the second company in history to achieve sustained commercial production from a transgenic animal platform, a milestone historically associated with ATryn, later incorporated into Sanofi following its acquisition of Genzyme.
The broader narrative: while multiple startups pursued synthetic spider silk after Kraig’s early breakthroughs, and raised significant capital, most have pivoted. Even DuPont, which developed nylon in the 1930s and later explored synthetic spider silk production, was unable to commercialize native-quality fibers.
Investors are now watching for confirmation of initial deliveries to previously disclosed global brand partners in luxury fashion, performance sportswear, and athletic equipment the step that could shift KBLB from research story to specialty materials platform.
Gilead Sciences to Acquire Arcellx
In large-cap biotech, consolidation continues.
Gilead Sciences announced a definitive agreement to acquire Arcellx (NASDAQ:ACLX) for
The acquisition gives Gilead full control of anitocabtagene autoleucel (anito-cel), a BCMA-directed CAR T-cell therapy for relapsed or refractory multiple myeloma. The FDA has accepted the BLA for anito-cel, with a PDUFA action date of December 23, 2026.
Daniel O’Day, Chairman and CEO of Gilead, stated, “Beyond the potential launch this year, anito-cel could become a foundational treatment for multiple myeloma over time, including earlier lines of therapy. In addition, the anito-cel D-domain BCMA binder could be important to our work in in vivo cell therapy, further strengthening our potential in oncology and inflammation.”
Arcellx CEO Rami Elghandour added, “We are fortunate to have found a world-class partner in Gilead, which has the expertise to carry forward Arcellx’s legacy.”
The deal builds on a 2022 collaboration between Arcellx and Kite, a Gilead company, and eliminates profit-sharing and milestone structures, consolidating economics under Gilead as it deepens its oncology footprint.
For biotech investors, the takeaway is clear: validated cell therapy platforms with regulatory traction remain premium assets.
ImmunityBio Reports
Momentum is also evident at ImmunityBio (NASDAQ:IBRX), which reported approximately
The company also reported a
Founder Dr. Patrick Soon-Shiong stated, “In under two years from initial FDA approval, ImmunityBio has built a global commercial footprint spanning 33 countries across four regulatory jurisdictions.”
Notably, Saudi regulators granted conditional accelerated approval for ANKTIVA in combination with checkpoint inhibitors for metastatic non-small cell lung cancer, marking the therapy’s first approval beyond bladder cancer.
With multiple randomized trials underway and long-term patent protection extending beyond 2035, IBRX is positioning ANKTIVA as a backbone immunotherapy platform rather than a single-indication asset.
Getty Images and Shutterstock Clear DOJ Review
In media and digital content, Getty Images (NYSE:GETY) and Shutterstock received unconditional antitrust clearance from the U.S. Department of Justice for their proposed merger of equals.
Getty Images CEO Craig Peters stated, “With today’s DOJ clearance, we take a significant step forward in bringing together these two companies and unlocking opportunities to strengthen our financial foundation and invest in our future.”
The companies are still engaged with the U.K. Competition and Markets Authority, with a final decision expected by April 19. If completed, the merger is expected to deliver SG&A and CAPEX synergies while strengthening their competitive positioning in a rapidly evolving visual content and generative AI landscape.
Please click here to read the full Kraig Labs analyst report on 247marketnews.com.
Interested persons can order a copy of the magazine from National Geographic at https://ngsingleissues.nationalgeographic.com/natgeo-march-2026.
You can purchase a digital copy of the article directly from National Geographic at https://www.nationalgeographic.com/science/article/spider-silk-silkworm-genetic-engineering
** Photography by Mark Thiessen, NGM Staff, Image Copyright: National Geographic Magazine
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) is a biotechnology company focused on the development and commercialization of spider silk-based fiber technologies. Through its proprietary silkworm-based genetic engineering platform, Kraig Labs produces high-performance, cost-effective, and scalable spider silk materials for use in defense, performance apparel, technical textiles, and medical applications.
For more information about Kraig Labs’ spider silk technology and partnership opportunities, visit www.kraiglabs.com
About 24/7 Market News
In today's fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247marketnews.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24/7 is a third-party media provider that owns KBLB shares, which are on deposit and may be sold at the editor’s discretion, and has been compensated for providing ongoing KBLB market outreach and other services.. This press release may include technical analysis and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions.
For further information, please visit 247marketnews.com or https://go.247marketnews.com/kblb-disclosure/
CONTACT:
24/7 Market News
Editor@247marketnews.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2e7bb94e-d38b-4cb2-bade-59045b03d474
FAQ
What did Kraig Biocraft Laboratories (KBLB) announce about commercial production in March 2026?
How might Gilead's acquisition of Arcellx (ACLX) affect the oncology landscape?
What are ImmunityBio's (IBRX) 2025 commercial results for ANKTIVA?
Has the DOJ cleared the Getty Images and Shutterstock merger and what remains outstanding?
What regulatory milestone matters for Arcellx's anito-cel and its timeline?
How could National Geographic coverage affect Kraig Biocraft Laboratories (KBLB) investor interest?
